Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2017

View Archived Issues

Vaccibody reports results from phase I of VB C-01 study

[203Pb]-AR-RMX completes exploratory trial in somatostatin receptor-positive neuroendocrine tumors

Devonian to begin testing Thykamine in atopic dermatitis

Ultragenyx reaches agreement on burosumab BLA clinical data package

EMA gives positive opinion to Gilead Sciences' Vosevi

FDA gives breakthrough therapy designation to CR-845 from Cara Therapeutics

EMA's CHMP supports approval of adalimumab biosimilar Imraldi

Preliminary phase I/II results for epacadostat plus pembrolizumab in patients with SCCHN

Alexion Pharmaceuticals receives positive opinion from EMA to extend Soliris indication

Eisai seeks Japanese approval for Lenvima in HCC

EMA committee hands down positive opinion on pediatric formulation of Mimpara

Merck & Co. discloses leukotriene BLT1 receptor antagonists

Novel SSAO inhibitor UD-014 ameliorates experimental diabetic nephropathy

Gan & Lee Pharmaceuticals divulges CDK4 and CDK6 inhibitors

Naeja-Rgm Pharmaceuticals patents cephem derivatives

EMA's CHMP grants positive opinion for tivozanib for the first-line treatment of advanced RCC

Daiichi Sankyo develops probe to image B7-H3-expressing tumors

U.K. MHRA approves Redx's phase Ib/IIa trial of porcupine inhibitor RXC-004

AstraZeneca's Faslodex receives positive opinion in E.U.

Roche identifies cannabinoid CB2 receptor agonists

EMA supports E.U. approval of Maviret for HCV

Hinova Pharmaceuticals discovers URAT1 inhibitors

Takeda and Biological E partner on low-cost combination vaccines

Merck KGaA's cladribine earns positive opinion from CHMP for relapsing forms of multiple sclerosis

EMA committee recommends approval of Kisqali

Signs of efficacy seen with AMG-557 in systemic lupus erythematosus trial

FDA approves Bevyxxa for hospital and extended-duration prophylaxis of VTE

EC approves eslicarbazepine acetate monotherapy for newly diagnosed partial-onset epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...